نتایج جستجو برای: tfv

تعداد نتایج: 187  

2017
Nobubelo K. Ngandu Jonathan M. Carlson Denis R. Chopera Nonkululeko Ndabambi Quarraisha Abdool Karim Salim Abdool Karim Carolyn Williamson

BACKGROUND Women in the CAPRISA 004 trial assigned to use 1% tenofovir (TFV) microbicide gel, who became HIV-1 infected, had higher viral load set-point and slower antibody avidity maturation compared with placebo participants. We investigated whether TFV gel was selected for viruses with altered genetic characteristics. SETTING The participants of the CAPRISA 004 trial (n = 28 TFV and 43 pla...

2017
Nilesh Chatterjee Deepak Patil Rajashree Kadam Genevie Fernandes

India has 274 million tobacco users and a tobacco use prevalence of 38% in rural areas. Tobacco consumption causes 1 million deaths and costs the health system nearly US$23 billion annually. Tobacco control policies exist but lack proper implementation. In this article, we review the Tobacco-free Village (TfV) program conducted in Maharashtra state in India and describe its process to help vill...

2012
Peter L. Anderson

tablets is a robust intervention for preventing HIV acquisition among men who have sex with men. 99% for two, four, and seven doses per week, respectively. These findings suggest that PrEP using oral FTC-TDF model was used to analyze the STRAND TFV-DP concentrations, the predicted HIV risk reductions were 76, 96, and PBMCs (31 to 47) after seven doses per week. When the iPrEx study's regression...

Journal: :Enfermedades infecciosas y microbiologia clinica 2017
Antonio Rivero José Antonio Pérez-Molina Antonio Javier Blasco José Ramón Arribas Víctor Asensi Manuel Crespo Pere Domingo José Antonio Iribarren Pablo Lázaro José López-Aldeguer Fernando Lozano Esteban Martínez Santiago Moreno Rosario Palacios Juan Antonio Pineda Federico Pulido Rafael Rubio Jesús Santos Javier de la Torre Montserrat Tuset Josep M Gatell

INTRODUCTION GESIDA and the Spanish National AIDS Plan panel of experts have recommended preferred (PR), alternative (AR) and other regimens (OR) for antiretroviral therapy (ART) as initial therapy in HIV-infected patients for 2017. The objective of this study was to evaluate the costs and the efficiency of initiating treatment with PR and AR. METHODS Economic assessment of costs and efficien...

2013
Yajing Gao David F. Katz

BACKGROUND Trials of a vaginal Tenofovir gel for pre-exposure prophylaxis (PrEP) for HIV have given conflicting results. Knowledge of concentrations of Tenofovir and its active form Tenofovir diphosphate, at putative sites of anti-HIV functioning, is central to understanding trial outcomes and design of products and dosage regimens. Topical Tenofovir delivery to the vaginal environment is compl...

Journal: :Antimicrobial agents and chemotherapy 2011
Trevor Hawkins Wenoah Veikley Lucie Durand-Gasselin Darius Babusis Y Sunila Reddy John F Flaherty Adrian S Ray

Studies were conducted to determine if there is a mechanistic basis for reports of suboptimal virologic responses and concerns regarding the safety of regimens containing the combination of tenofovir (TFV) disoproxil fumarate (TDF) and didanosine (ddI) by assessing the pharmacokinetic consequences of coadministration of these drugs on intracellular nucleotides. This was a prospective and longit...

Journal: :The Journal of infectious diseases 2015
Rachel A Bender Ignacio Tara Perti Amalia S Magaret Sharanya Rajagopal Claire E Stevens Meei-Li Huang Stacy Selke Christine Johnston Jeanne Marrazzo Anna Wald

BACKGROUND Tenofovir is a potent anti-human immunodeficiency virus (HIV) agent that decreased risk of herpes simplex virus type 2 (HSV-2) acquisition in HIV pre-exposure prophylaxis trials. Whether tenofovir has utility in established HSV-2 disease is unclear. METHODS We randomized immunocompetent women with symptomatic HSV-2 infection to oral tenofovir disoproxil fumarate (TDF)/placebo vagin...

2017
Alex Carballo-Diéguez Ivan C Balán William Brown Rebecca Giguere Curtis Dolezal Cheng-Shiun Leu Mark A Marzinke Craig W Hendrix Jeanna M Piper Barbra A Richardson Cynthia Grossman Sherri Johnson Kailazarid Gomez Stephanie Horn Ratiya Pamela Kunjara Na Ayudhya Karen Patterson Cindy Jacobson Linda-Gail Bekker Suwat Chariyalertsak Anupong Chitwarakorn Pedro Gonzales Timothy H Holtz Albert Liu Kenneth H Mayer Carmen Zorrilla Javier Lama Ian McGowan Ross D Cranston

Trials to assess microbicide safety require strict adherence to prescribed regimens. If adherence is suboptimal, safety cannot be adequately assessed. MTN-017 was a phase 2, randomized sequence, open-label, expanded safety and acceptability crossover study comparing 1) daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), 2) daily use of reduced-glycerin 1% tenofovir (RG-TFV) gel ap...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015
Tim R Cressey Anchalee Avihingsanon Guttiga Halue Prattana Leenasirimakul Pra-Ornsuda Sukrakanchana Yardpiroon Tawon Nirattiya Jaisieng Gonzague Jourdain Anthony T Podany Courtney V Fletcher Virat Klinbuayaem Chureeratana Bowonwatanuwong

BACKGROUND The approved tenofovir disoproxil fumarate (TDF) dose of 300 mg every 48 hours for adults with moderate renal impairment is often confusing and inconvenient. Using a new TDF formulation, we compared the pharmacokinetics of the standard dose with a dose of 150 mg once daily in HIV-infected adults. METHODS This was an open-label pharmacokinetic study. Virologically suppressed HIV-inf...

Journal: :Open Forum Infectious Diseases 2023

Abstract Background Food insecurity has been linked to suboptimal antiretroviral therapy (ART) adherence in persons with HIV (PWH). This association not evaluated using tenofovir diphosphate dried blood spots (TFV-DP DBS), a biomarker of cumulative ART and exposure. Methods Within prospective South African cohort treatment-naïve PWH initiating ART, subset participants measured TFV-DP DBS values...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید